Treatment adherence in chronic disease.

Research has addressed the problem of poor adherence for the past 4 decades. Much of the research has focused on the prevalence and predictors of adherence, research methodologies, and the development of measures of adherence. To a much lesser extent, attention has been given to intervention studies designed to evaluate strategies to improve adherence to treatment regimens. This article provides an up-to-date review of the literature on medication adherence in chronic disease.

Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature.

The fluoroquinolones represent a new class of antimicrobial agents with a broad spectrum of activity. We report three cases of acute renal failure following ciprofloxacin in patients without a previous history of renal insufficiency. The average baseline creatinine was 1.1 mg/dl and rose to an average of 4.0 mg/dl during therapy. The length of antecedent ciprofloxacin therapy ranged from several days to several weeks. Other causes of acute renal failure and postobstructive uropathy were excluded. Kidney size was normal-to-increased. Gallium scans were positive in one of two patients studied. Peripheral eosinophilia developed in one case, suggesting an acute hypersensitivity reaction to the drug. The acute renal failure in all cases was non-oliguric and was completely reversed after discontinuation of ciprofloxacin. In two of the three reported cases there was an increased creatinine to BUN ratio, but increased production of creatinine (i.e., rhabdomyolysis) was unlikely with a normal serum creatinine phosphokinase (CPK). In addition, we performed in vitro studies which eliminated the possibility of methodological artifact. The nephrotoxicity of the quinolones has been linked to the development of crystalluria in experimental animals. However, in humans, crystalluria is unlikely and renal damage has not been noted. There have been only two previous case reports of acute renal failure due to oral ciprofloxacin therapy. In one, biopsy showed acute interstitial nephritis. We conclude that oral ciprofloxacin therapy may lead to acute renal failure secondary to tubulointerstitial nephritis characterized by an increased creatinine to BUN ratio. Patients placed on ciprofloxacin therapy need to be followed closely.

Improving medical care for West Virginia seniors.

Using data published by the Health Care Financing Administration (HCFA), supplemented with information obtained from West Virginia Medicare claims data and Medicare hospital records, we compared the performance of West Virginia physicians and hospitals on 22 quality of care indicators for six common conditions. The conditions are myocardial infarction, congestive heart failure, atrial fibrillation, stroke, breast cancer screening and pneumonia. Quality indicator performance for most indicators in West Virginia from 1997-98 was lower than the average of the 19 states with data collected at the same time. For some indicators, such as early use of beta blockers following myocardial infarction (52.7%), administration of influenza vaccine (58.2%), and warfarin prescription to atrial fibrillation patients (45.1%), the state's care ranked near the bottom. However, quality scores varied widely among West Virginia health care providers, suggesting that statewide improvement in care is feasible. Ongoing efforts among physicians, hospitals and the peer review organization are aimed at achieving such improvement.

Guidelines for the use of blood transfusions.

Over 11 million units of red blood cells are transfused each year in the United States at a cost of over $2 billion. This paper reviews the indications for and the risks of red blood cell transfusions, and provides guidelines for transfusions in both surgical and non-surgical settings.

Treatment of acute vascular rejection with immunoadsorption.

BACKGROUND: Acute vascular rejection (AVR) is characterized by vascular injury and systolic graft dysfunction and is often associated with elevated panel reactive antibodies (PRAs) to HLA antigens. Plasmapheresis has been shown to improve the otherwise poor prognosis of AVR, but its use is often complicated and limited by hypotension. METHODS AND RESULTS: In three cardiac transplant recipients with severe hemodynamic compromise during AVR, refractory to standard therapy, extracorporeal immunoadsorption was performed using a protein A column. Plasma was removed at 10 to 20 cm3/min, passed through the column, and reinfused. All three patients had negative pretransplant PRAs. PRA rose before or during AVR and became negative in all three patients following immunoadsorption. Time course and number of treatments required to decrease PRA to < 5% varied. Concomitant with a decrease in PRA, histological findings and ventricular function improved and normalized. Ejection fraction rose from 23 +/- 2 to 56 +/- 8% and shortening fraction from 14 +/- 7 to 36 +/- 7%, P < .05 (both). One patient died from infection 2 months after resolution of AVR; the other two patients are alive 25 and 31 months after AVR with normal left ventricular function and coronary arteries. In both, since initial immunoadsorption course, PRA has remained negative and no rejection has occurred. In two patients, a circulating donor-specific or donor-related anti-HLA class I antibody was identified and removed by protein A column. CONCLUSIONS: Our preliminary data suggest that (1) immunoadsorption is effective in removing circulating immunoglobulins and is well tolerated; (2) AVR is preceded by or associated with circulating antibodies against HLA class I antigens; (3) their removal is temporarily associated with recovery of graft function and normalization of biopsy; and (4) anti-HLA class I antibodies can mediate vascular injury if they appear in the post-transplant period.

Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function.

Amantadine is useful for the prevention and treatment of influenza A and for the treatment of Parkinson's disease and drug-induced extrapyramidal disorders. We have compared the pharmacokinetics of amantadine in patients with impaired or negligible renal function to that in normal subjects. The half-life of elimination in subjects with normal renal function was 11.8 +/- 2.1 hours (range, 9.7 to 14.5 h). Eight patients with various degrees of renal insufficiency (creatinine clearance from 43.1 to 5.9 mL/min . 1.73 m2) had half-lives of elimination from 18.5 h to 33.8 days. We also studied 10 patients on thrice-weekly hemodialysis. Assuming complete bioavailability of the drug, less than 5% of the dose was removed by each 4-hour hemodialysis. The mean half-life of elimination during chronic hemodialysis was 8.3 days (range, 7.0 to 10.3). We present guidelines for use of amantadine in patients with impaired renal function, including those on maintenance hemodialysis.

Cheap, accurate and rapid allele frequency estimation of single nucleotide polymorphisms by primer extension and DHPLC in DNA pools.

At present, the cost of genotyping single nucleotide polymorphisms (SNPs) in large numbers of subjects poses a formidable problem for molecular genetic approaches to complex diseases. We have tested the possibility of using primer extension and denaturing high performance liquid chromatography to estimate allele frequencies of SNPs in pooled DNA samples. Our data show that this method should allow the accurate estimation of absolute allele frequencies in pooled samples of DNA and also of the difference in allele frequency between different pooled DNA samples. This technique therefore offers an efficient and cheap method for genotyping SNPs in large case-control and family-based association samples.

A longitudinal study of bone disease after successful renal transplantation.

A retrospective study of 100 patients followed for 1-4 years after successful renal transplantation was undertaken to assess the amelioration of previously present metabolic bone disease and to determine the risk factors associated with the development of osteonecrosis. 42% of patients showed some evidence of bony abnormality. Following transplantation, there was slow but progressive resolution in the X-ray changes of hyperparathyroidism but not of osteoporosis. 14% of patients developed osteonecrosis in the posttransplant period with the femoral head the most common site involved (72% of patients). Osteonecrosis could not be related to average steroid dose, number of steroid pulses, or the preexistence of metabolic bone disease.